Search

Your search keyword '"Diener, Hans-Christoph"' showing total 4,265 results
Start Over Author "Diener, Hans-Christoph"
4,265 results on '"Diener, Hans-Christoph"'

6. Time to treatment with bridging intravenous alteplase before endovascular treatment:subanalysis of the randomized controlled SWIFT-DIRECT trial.

Author

Meinel, Thomas, Kaesmacher, Johannes, Buetikofer, Lukas, Strbian, Daniel, Eker, Omer, Cognard, Christophe, Mordasini, Pasquale, Deppeler, Sandro, Mendes Pereira, Vitor, Albucher, Jean, Darcourt, Jean, Bourcier, Romain, Guillon, Benoit, Papagiannaki, Chrysanthi, Costentin, Guillaume, Sibolt, Gerli, Räty, Silja, Gory, Benjamin, Richard, Sébastien, Liman, Jan, Ernst, Marielle, Boulanger, Marion, Barbier, Charlotte, Mechtouff, Laura, Zhang, Liqun, Marnat, Gaultier, Sibon, Igor, Nikoubashman, Omid, Reich, Arno, Consoli, Arturo, Weisenburger, David, Requena, Manuel, Garcia-Tornel, Alvaro, Saleme, Suzana, Moulin, Solène, Pagano, Paolo, Saliou, Guillaume, Carrera, Emmanuel, Janot, Kevin, Boix, Marti, Pop, Raoul, Della Schiava, Lucie, Luft, Andreas, Piotin, Michel, Gentric, Jean, Pikula, Aleksandra, Pfeilschifter, Waltraud, Arnold, Marcel, Siddiqui, Adnan, Froehler, Michael, Furlan, Anthony, Chapot, René, Wiesmann, Martin, Machi, Paolo, Diener, Hans-Christoph, Kulcsar, Zsolt, Bonati, Leo, Bassetti, Claudio, Escalard, Simon, Liebeskind, David, Saver, Jeffrey, Fischer, Urs, and Gralla, Jan

Subjects
Thrombectomy, Thrombolysis, Humans, Female, Aged, Male, Tissue Plasminogen Activator, Stroke, Time-to-Treatment, Thrombolytic Therapy, Thrombectomy, Brain Ischemia, Treatment Outcome, Fibrinolytic Agents
Abstract

BACKGROUND: We hypothesized that treatment delays might be an effect modifier regarding risks and benefits of intravenous thrombolysis (IVT) before mechanical thrombectomy (MT). METHODS: We used the dataset of the SWIFT-DIRECT trial, which randomized 408 patients to IVT+MT or MT alone. Potential interactions between assignment to IVT+MT and expected time from onset-to-needle (OTN) as well as expected time from door-to-needle (DTN) were included in regression models. The primary outcome was functional independence (modified Rankin Scale (mRS) 0-2) at 3 months. Secondary outcomes included mRS shift, mortality, recanalization rates, and (symptomatic) intracranial hemorrhage at 24 hours. RESULTS: We included 408 patients (IVT+MT 207, MT 201, median age 72 years (IQR 64-81), 209 (51.2%) female). The expected median OTN and DTN were 142 min and 54 min in the IVT+MT group and 129 min and 51 min in the MT alone group. Overall, there was no significant interaction between OTN and bridging IVT assignment regarding either the functional (adjusted OR (aOR) 0.76, 95% CI 0.45 to 1.30) and safety outcomes or the recanalization rates. Analysis of in-hospital delays showed no significant interaction between DTN and bridging IVT assignment regarding the dichotomized functional outcome (aOR 0.48, 95% CI 0.14 to 1.62), but the shift and mortality analyses suggested a greater benefit of IVT when in-hospital delays were short. CONCLUSIONS: We found no evidence that the effect of bridging IVT on functional independence is modified by overall or in-hospital treatment delays. Considering its low power, this subgroup analysis could have missed a clinically important effect, and exploratory analysis of secondary clinical outcomes indicated a potentially favorable effect of IVT with shorter in-hospital delays. Heterogeneity of the IVT effect size before MT should be further analyzed in individual patient meta-analysis of comparable trials. TRIAL REGISTRATION NUMBER: URL: https://www. CLINICALTRIALS: gov ; Unique identifier: NCT03192332.

Published
2023

12. Monitoring for atrial fibrillation prior to patent foramen ovale closure after cryptogenic stroke

Author

Diener, Hans-Christoph, Wachter, Rolf, Wong, Andrew, Thijs, Vincent, Schnabel, Renate B, Ntaios, George, Kasner, Scott, Rothwell, Peter M, Passman, Rod, Saver, Jeffrey L, Albers, Bert A, and Bernstein, Richard A

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Research, Neurosciences, Brain Disorders, Heart Disease, Cardiovascular, Detection, screening and diagnosis, 2.1 Biological and endogenous factors, Aetiology, 4.2 Evaluation of markers and technologies, Stroke, Humans, Atrial Fibrillation, Foramen Ovale, Patent, Natriuretic Peptide, Brain, Ischemic Stroke, Risk Factors, Cryptogenic stroke, atrial fibrillation, patent foramen ovale closure, cardiac rhythm monitoring, stroke recurrence, monitoring strategy, Clinical Sciences, Neurology & Neurosurgery, Clinical sciences, Allied health and rehabilitation science
Abstract

BackgroundPatients who had a cryptogenic stroke (CS) suspected to be causally related to a patent foramen ovale (PFO) are candidates for percutaneous PFO closure. In such patients, it is important to screen for atrial fibrillation (AF). Limited guidance is available regarding AF monitoring strategies in CS patients with PFO addressing optimal monitoring technology and duration.AimTo provide a narrative review of cardiac rhythm monitoring in CS patients considered for PFO closure, including current practices, stroke recurrences after CS, findings from monitoring studies in CS patients, and predictors for AF detection published in the literature. To propose a personalized strategy for cardiac monitoring in CS patients, accounting for aspects predicting AF detection.Summary of reviewAF detection in CS patients is predicted by age, left atrial enlargement, prolonged PR interval, frequent premature atrial contractions, interatrial conduction block, diabetes, prior brain infarctions, leukoaraiosis, elevated B-type natriuretic peptide (BNP)/N-terminal pro B-type natriuretic peptide (NT-proBNP) levels, and a family history of AF, as well as composed scores (e.g. CHA2DS2-VASc, atrial fibrillation in embolic stroke of undetermined source (AF-ESUS)). The causal role of the PFO may be accounted for by the risk of paradoxical embolism (RoPE) score and/or the PFO-Associated Stroke Causal Likelihood (PASCAL) classification.ConclusionA personalized approach to AF detection in CS patients is proposed, accounting for the likelihood of AF detection and aimed at obtaining sufficient confidence regarding the absence of AF in patients considered for PFO closure. In addition, the impact of high-risk PFO features on the monitoring strategy is discussed.

Published
2023

16. Hirnblutungen

Author

Diener, Hans-Christoph, primary, Goldbrunner, Roland, additional, and Forsting, Michael, additional

Published
2024
Full Text
View/download PDF

17. Zerebrale Ischämie

Author

Diener, Hans-Christoph, primary, Nickenig, Georg, additional, Forsting, Michael, additional, and Goldbrunner, Roland, additional

Published
2024
Full Text
View/download PDF

24. Medication overuse headache

Author

Ashina, Sait, Terwindt, Gisela M., Steiner, Timothy J., Lee, Mi Ji, Porreca, Frank, Tassorelli, Cristina, Schwedt, Todd J., Jensen, Rigmor H., Diener, Hans-Christoph, and Lipton, Richard B.

Published
2023
Full Text
View/download PDF

25. Tobacco use and risk of acute stroke in 32 countries in the INTERSTROKE study: a case–control study

Author

Wang, Xingyu, Liu, Xin, O’Donnell, Martin J., McQueen, Matthew, Sniderman, Allan, Pare, Guillaume, Hankey, Graeme J., Rangarajan, Sumathy, Chin, Siu Lim, Rao-Melacini, Purnima, Ferguson, John, Xavier, Denis, Zhang, Hongye, Lisheng, Liu, Pais, Prem, Lopez-Jaramillo, Patricio, Damasceno, Albertino, Langhorne, Peter, Rosengren, Annika, Dans, Antonio L., Elsayed, Ahmed, Avezum, Alvaro, Mondo, Charles, Judge, Conor, Diener, Hans-Christoph, Ryglewicz, Danuta, Czlonkowska, Anna, Pogosova, Nana, Weimar, Christian, Iqbal, Romana, Diaz, Rafael, Yusoff, Khalid, Yusufali, Afzalhussein, Oguz, Aytekin, Penaherrera, Ernesto, Lanas, Fernando, Ogah, Okechukwu S., Ogunniyi, A., Iversen, Helle K., Malaga, German, Rumboldt, Zvonko, Oveisgharan, Shahram, Al Hussain, Fawaz, Nilanont, Yongchai, and Yusuf, Salim

Published
2024
Full Text
View/download PDF

28. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial

Author

Sharma, Mukul, Molina, Carlos A, Toyoda, Kazunori, Bereczki, Daniel, Bangdiwala, Shrikant I, Kasner, Scott E, Lutsep, Helmi L, Tsivgoulis, Georgios, Ntaios, George, Czlonkowska, Anna, Shuaib, Ashfaq, Amarenco, Pierre, Endres, Matthias, Yoon, Byung-Woo, Tanne, David, Toni, Danilo, Yperzeele, Laetitia, von Weitzel-Mudersbach, Paul, Sampaio Silva, Gisele, Avezum, Alvaro, Dawson, Jesse, Strbian, Daniel, Tatlisumak, Turgut, Eckstein, Jens, Ameriso, Sebastián F, Weber, Joerg R, Sandset, Else Charlotte, Goar Pogosova, Nana, Lavados, Pablo M, Arauz, Antonio, Gailani, David, Diener, Hans-Christoph, Bernstein, Richard A, Cordonnier, Charlotte, Kahl, Anja, Abelian, Grigor, Donovan, Mark, Pachai, Chahin, Li, Danshi, and Hankey, Graeme J

Published
2024
Full Text
View/download PDF

31. Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

Author

Goßrau, Gudrun, Förderreuther, Stefanie, Ruscheweyh, Ruth, Ruschil, Victoria, Sprenger, Till, Lewis, David, Kamm, Katharina, Freilinger, Tobias, Neeb, Lars, Malzacher, Volker, Meier, Uwe, Gehring, Klaus, Kraya, Torsten, Dresler, Thomas, Schankin, Christoph J., Gantenbein, Andreas R., Brössner, Gregor, Zebenholzer, Karin, Diener, Hans-Christoph, Gaul, Charly, and Jürgens, Tim P.

Published
2023
Full Text
View/download PDF

32. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials

Author

Klug, Didier, Casolla, Barbara, Puy, Laurent, Coffee, Morgane, Kuchcinski, Grégory, Labreuche, Julien, van Nieuwenhuizen, Koen M., Algra, Ale, van Gelder, Isabelle C., Kappelle, L. Jaap, Rinkel, Gabriel J.E., Schutgens, Roger E.G., Khatri, Pooja, Conwit, Robin, Falcone, Guido, Elm, Jordan, Anderson, Craig S., Song, Lili, Pandian, Jeyaraj, Hart, Robert G., Sharma, Mukul, Aref, Hany, Tarhuni, Wadea, Fabregas, Joan Marti, Diener, Hans-Christoph, Endres, Matthias, Lemmens, Robin, Kwon, Sun U., Lee, Byung-Chul, Ameriso, Sebastian, Milling, Truman J., Kasner, Scott E., Mikulik, Robert, Xavier, Denis, Beer, Ronny, Toni, Danilo, Eckstein, Jens, Seiffge, David, Ferro, Jose M., Tsivgoulis, Georgios, Sharma, Sanjib K., Wei-Liou, Chia, Hohnloser, Stefan H., Katsanos, Aristeidis, Bosch, Jackie, Healey, Jeff, Eikelboom, John, Khaw, Alexander, Gladstone, David, Pikula, Aleksandra, Coutts, Shelagh, Smith, Eric E., Butcher, Ken, Field, Thalia, Gioia, Laura, Stapf, Christian, Halse, Omid, Ringleb, Peter, Enzinger, Christian, Sibon, Igor, Montaner, Joan, Caso, Valeria, Heuschmann, Peter, Lip, Gregory Y.H., Haefeli, Walter, Debette, Stefanie, Dennis, Martin S., Wyller, Torgeir Bruun, Rønning, Ole M., Eilertsen, Helle, Ihle-Hansen, Hege, Sandset, Else Charlotte, Pennlert, Johanna, Glader, Eva-Lotta, Kruuse, Christina, Wester, Per, Carlsson, Maria, Forfang, Elisabeth, Al-Shahi Salman, Rustam, Stephen, Jacqueline, Tierney, Jayne F, Lewis, Steff C, Newby, David E, Parry-Jones, Adrian R, White, Philip M, Connolly, Stuart J, Benavente, Oscar R, Dowlatshahi, Dar, Cordonnier, Charlotte, Viscoli, Catherine M, Sheth, Kevin N, Kamel, Hooman, Veltkamp, Roland, Larsen, Kristin T, Hofmeijer, Jeannette, Kerkhoff, Henk, Schreuder, Floris H B M, Shoamanesh, Ashkan, Klijn, Catharina J M, and van der Worp, H Bart

Published
2023
Full Text
View/download PDF

34. Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation

Author

Diener, Hans-Christoph, Hankey, Graeme J, Easton, J Donald, Lip, Gregory YH, Hart, Robert G, and Caso, Valeria

Subjects
Nutrition, Brain Disorders, Clinical Research, Prevention, Stroke, Hematology, Blood, Cardiovascular, Good Health and Well Being, Non-vitamin K oral anticoagulants, Atrial fibrillation, TIA, Secondary stroke prevention, Warfarin, Embolic stroke of undetermined source, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology
Abstract

The aims of this article are to review the evidence regarding the use of non-vitamin K oral anticoagulants (NOACs) for secondary stroke prevention as compared to vitamin K antagonists in patients with atrial fibrillation (AF) and in patients with embolic strokes of uncertain source (ESUS), and when to initiate or resume anticoagulation after an ischaemic stroke or intracranial haemorrhage. Four large trials compared NOACs with warfarin in patients with AF. In our meta-analyses, the rate of all stroke or systemic embolism (SE) was 4.94% with NOACs vs. 5.73% with warfarin. Among the patients with AF and previous transient ischaemic attack or ischaemic stroke, the rate of haemorrhagic stroke was halved with a NOAC vs. warfarin, and the rate of major bleeding was 5.7% with a NOAC vs. 6.4% with warfarin. There was no significant difference in mortality. In a trial comparing apixaban with aspirin in patients with AF, the rate of stroke or SE was 2.4% at 1 year with apixaban vs. 9.2% at 1 year with aspirin and the rates of major bleeding were 4.1% with apixaban vs. 2.9% with aspirin. Data from registries confirmed the results from the randomized trials. Initiation or resumption of anticoagulation after ischaemic stroke or cerebral haemorrhage depends on the size and severity of stroke and the risk of recurrent bleeding. Two large trials tested the hypothesis that NOACs are more effective than 100 mg aspirin in patients with ESUS. Neither trial showed a significant benefit of the NOAC over aspirin. In the meta-analysis, the rate all stroke or SE was 4.94% with NOACs vs. 5.73% with warfarin and the rate of haemorrhagic stroke was halved with a NOAC. The four NOACs had broadly similar efficacy for the major outcomes in secondary stroke prevention.

Published
2020

35. Antithrombotic Treatment of Embolic Stroke of Undetermined Source

Author

Diener, Hans-Christoph, Sacco, Ralph L, Easton, J Donald, Granger, Christopher B, Bar, Michal, Bernstein, Richard A, Brainin, Michael, Brueckmann, Martina, Cronin, Lisa, Donnan, Geoffrey, Gdovinová, Zuzana, Grauer, Claudia, Kleine, Eva, Kleinig, Timothy J, Lyrer, Philippe, Martins, Sheila, Meyerhoff, Juliane, Milling, Truman, Pfeilschifter, Waltraud, Poli, Sven, Reif, Michal, Rose, David Z, Šaňák, Daniel, and Schäbitz, Wolf-Rüdiger

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Brain Disorders, Clinical Trials and Supportive Activities, Stroke, Hematology, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Aged, 80 and over, Aspirin, Dabigatran, Double-Blind Method, Female, Fibrinolytic Agents, Humans, Intracranial Embolism, Kidney Diseases, Male, Middle Aged, Recurrence, anticoagulants, atrial fibrillation, cardiovascular disease, risk factors, secondary prevention, Cardiorespiratory Medicine and Haematology, Neurosciences, Neurology & Neurosurgery, Clinical sciences, Allied health and rehabilitation science
Abstract

Background and Purpose- The RE-SPECT ESUS trial (Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) tested the hypothesis that dabigatran would be superior to aspirin for the prevention of recurrent stroke in patients with embolic stroke of undetermined source. This exploratory subgroup analysis investigates the impact of age, renal function (both predefined), and dabigatran dose (post hoc) on the rates of recurrent stroke and major bleeding. Methods- RE-SPECT ESUS was a multicenter, randomized, double-blind trial of dabigatran 150 or 110 mg (for patients aged ≥75 years and/or with creatinine clearance 30 to

Published
2020

41. Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention

Author

Sharma, Mukul, Molina, Carlos A., Toyoda, Kazunori, Bereczki, Daniel, Kasner, Scott E., Lutsep, Helmi L., Tsivgoulis, Georgios, Ntaios, George, Czlonkowska, Anna, Shuaib, Ashfaq, Amarenco, Pierre, Endres, Matthias, Diener, Hans Christoph, Gailani, David, Kahl, Anja, Donovan, Mark, Perera, Vidya, Li, Danshi, and Hankey, Graeme J.

Published
2022
Full Text
View/download PDF

44. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial

Author

Alonso, Angelika, Arquizan, Caroline, Barreau, Xavier, Beaujeux, Rémy, Behme, Daniel, Boeckh-Behrens, Tobias, Boehme, Christian, Boix, Martí, Boulouis, Grégoire, Bricout, Nicolas, Broc, Nicolas, Cereda, Carlo W., Chabert, Emmanuel, Cho, Tae-Hee, Cianfoni, Alessandro, Costalat, Vincent, Denier, Christian, Di Maria, Frederico, du Mesnil de Rochemont, Richard, Fearon, Patricia, Ferrier, Anna, Fischer, Sebastian, Gauberti, Maxime, Gaudron, Marie, Gimenez, Laetitia, Globas, Christoph, Görtler, Michael, Goyal, Mayank, Hilker-Roggendorf, Ruediger, Hill, Michael D., Hua, Vi Tuan, Humbertjean, Lisa, Jansen, Olav, Jung, Simon, Kägi, Georg, Kelly, Michael E., Kleffner, Ilka, Knoflach, Michael, Nedeltchev, Krassen, Krause, Lars Udo, Lappalainen, Kimmo, Lefebvre, Margaux, Leyon, Joe, Liao, Liang, Liegey, Jean-Sebastien, Loehr, Christian, Michel, Patrik, Nannoni, Stefania, Nicholson, Patrick, Nico, Lorena, Obadia, Michael, Ognard, Julien, Ogungbemi, Ayokunle, Olivot, Jean-Marc, Escalard, Simon, Pasi, Marco, Peeling, Lissa, Perez, Jane, Petersen, Martina, Piechowiak, Eike, Raposo, Roberto, Räty, Silja, Reitz, Sarah C., Remollo, Sebastià, Remonda, Luca, Rennie, Ian, Requena, Manuel, Riabikin, Alexander, Riva, Roberto, Rouchaud, Aymeric, Rosi, Andrea, Rubiera, Marta, Spelle, Laurent, Schnieder, Marlena, Schaafsma, Joanna D., Schubert, Tilman, Schulz, Jörg B., Siddiqui, Mohammed, Soize, Sébastien, Sonnberger, Michael, Touze, Emmanuel, Triquenot, Aude, Turc, Guillaume, Vieira, Lucy, Ben Hassen, Wagih, Wagner, Judith N., Wasser, Katrin, Weber, Johannes, Wenz, Holger, Weisenburger-Lile, David, Wodarg, Fritz, Wolff, Valérie, Wunderlich, Silke, Fischer, Urs, Kaesmacher, Johannes, Strbian, Daniel, Eker, Omer, Cognard, Christoph, Plattner, Patricia S, Bütikofer, Lukas, Mordasini, Pasquale, Deppeler, Sandro, Pereira, Vitor M, Albucher, Jean François, Darcourt, Jean, Bourcier, Romain, Benoit, Guillon, Papagiannaki, Chrysanthi, Ozkul-Wermester, Ozlem, Sibolt, Gerli, Tiainen, Marjaana, Gory, Benjamin, Richard, Sébastien, Liman, Jan, Ernst, Marielle Sophie, Boulanger, Marion, Barbier, Charlotte, Mechtouff, Laura, Zhang, Liqun, Marnat, Gaultier, Sibon, Igor, Nikoubashman, Omid, Reich, Arno, Consoli, Arturo, Lapergue, Bertrand, Ribo, Marc, Tomasello, Alejandro, Saleme, Suzana, Macian, Francisco, Moulin, Solène, Pagano, Paolo, Saliou, Guillaume, Carrera, Emmanuel, Janot, Kevin, Hernández-Pérez, María, Pop, Raoul, Schiava, Lucie Della, Luft, Andreas R, Piotin, Michel, Gentric, Jean Christophe, Pikula, Aleksandra, Pfeilschifter, Waltraud, Arnold, Marcel, Siddiqui, Adnan H, Froehler, Michael T, Furlan, Anthony J, Chapot, René, Wiesmann, Martin, Machi, Paolo, Diener, Hans-Christoph, Kulcsar, Zsolt, Bonati, Leo H, Bassetti, Claudio L, Mazighi, Mikael, Liebeskind, David S, Saver, Jeffrey L, and Gralla, Jan

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results